Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Dingpei Long; Zahra Alghoul; Junsik Sung; Chunhua Yang; Didier Merlin

doi:10.3390/pharmaceutics15092331

Prevention of Colitis-Associated Cancer via Oral Administration of M13-Loaded Lipid Nanoparticles

Pharmaceutics. 2023 Sep 16;15(9):2331. doi: 10.3390/pharmaceutics15092331.

Authors

Dingpei Long¹, Zahra Alghoul^{1

2}, Junsik Sung¹, Chunhua Yang^{1

3}, Didier Merlin^{1

3}

Affiliations

¹ Digestive Disease Research Group, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
² Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA.
³ Gastroenterology Research, Atlanta Veterans Affairs Medical Center, Decatur, GA 30302, USA.

Abstract

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease, is known to increase the risk of colitis-associated cancer (CAC). CAC has been found to be unresponsive to standard chemotherapy regimens, and the current treatments do not utilize effective small-molecule drugs and colon-targeted delivery systems. Previous studies indicated that the M13-nano-liposome (NL) formulation can effectively target the colon and reshape the gut microbiota in ex vivo cultures, generating altered microbial metabolites that can efficiently prevent chronic UC. In this study, we tested the cancer cell uptake ability of the NL formulation and investigated the potential of the M13-NL formulation to prevent CAC in the azoxymethane (AOM)-exposed IL10^-/- mouse model. Our findings demonstrate that oral administration of M13-NL prevents tumor development in AOM-exposed IL10^-/- mice, suggesting that M13-NL is a promising oral drug formulation for preventing CAC.

Keywords: IL-10 knockout; M13; chronic inflammation-induced cancer; nano-liposome; ulcerative colitis (UC).

Abstract

Grants and funding